AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
progression free survival
Advertisement
Celcuity’s Gedatolisib Doubles Progression-Free Survival in Phase 3 Breast Cancer Trial
MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...
Ono’s ONO-4578 Improves Progression-Free Survival in Gastric Cancer Phase 2 Study
OSAKA, Japan, June 2, 2026 Ono Pharmaceutical announced positive Phase 2 clinical trial results for ONO-4578, its investigational oral...
Servier’s Emi-Le Shows Promise in Rare ACC Cancer Trial
BOSTON, June 1, 2026 Servier has announced encouraging new clinical findings for Emiltatug Ledadotin (Emi-Le), an investigational B7-H4-targeted antibody-drug...
Revolution Medicines Daraxonrasib Doubles Survival in PDAC
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Advertisements
Servier’s VORANIGO® Delivers More Than 44 Months of Progression-Free Survival in IDH-Mutant Glioma
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Cogent’s Bezuclastinib Gains FDA Priority Review for GIST
WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 Cogent Biosciences has announced a major regulatory milestone with the U.S....
Akeso Cadonilimab Combo Delivers Strong NSCLC Trial Results
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
Dizal Reports Phase 3 Breakthrough for ZEGFROVY in NSCLC
Shanghai, China | March 21, 2026 Dizal has announced positive topline results from its multinational Phase 3 WU-KONG28 clinical...
Advertisement
